Testing a new type of radiotherapy using an MR-Linac device
Feasibility of Imaging and Radiotherapy on a Novel 1.5 T Hybrid Magnetic Resonance Imaging - Linear Accelerator System (MR-Linac)
This study tests a new type of radiotherapy using a special machine that combines imaging and treatment to see if it can better target tumors while protecting healthy tissue.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 472 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | University Hospital Tuebingen Academic / other |
| Drugs / interventions | radiation |
| Locations | 1 site (Tübingen, Baden-Wurttemberg) |
| Trial ID | NCT04172753 on ClinicalTrials.gov |
What this trial studies
This study investigates the feasibility of using a 1.5 T MR-Linac, a hybrid device that combines magnetic resonance imaging and a linear accelerator for radiotherapy. The approach aims to improve treatment precision by utilizing superior soft tissue contrast and enabling daily plan adaptations. By assessing the feasibility of imaging and treatment with this novel technology, the study seeks to enhance target volume coverage while minimizing damage to surrounding healthy tissues.
Who should consider this trial
Good fit: Ideal candidates include adults aged 18 and older who require radiation therapy for conditions like rectal, head and neck, liver, breast, or prostate cancer.
Not a fit: Patients with contraindications for MRI, such as claustrophobia or certain metallic implants, as well as pregnant individuals, may not benefit from this study.
Why it matters
Potential benefit: If successful, this could lead to more effective and personalized radiotherapy treatments for various cancers.
How similar studies have performed: Other studies have shown promise with similar MR-guided radiotherapy approaches, indicating potential for success in this novel application.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * existing indication for radiation therapy * minimum age 18 years, no upper age limit * capacity for consent * Informed consent Exclusion Criteria: * contraindication for MRI (claustrophobia, metallic implants not applicable for MRI * pregnancy
Where this trial is running
Tübingen, Baden-Wurttemberg
- University Hospital Tübingen, Department of Radiation Oncology — Tübingen, Baden-Wurttemberg, Germany (Recruiting)
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.